Tech-heavy Asian bourses remained the worst performers in the region, with South Korea’s KOSPI and Hong Kong’s Hang Seng ...

Investing.com-- U.S. President Donald Trump on Monday evening sued the British Broadcasting Corporation (BBC) for defamation over editing footage of him for a documentary on the 2021 Capitol riots.

Growth remained largely skewed towards the services sector, with the flash Japan services PMI reading 52.5 in December, compared to 53.2 in the prior month. The services sector has been a key driver ...

SEOUL, Dec 15 (Reuters) - Korea Zinc said on Monday it will build a $7.4 billion critical minerals refinery in Tennessee that ...

NVIDIA Corporation (NASDAQ:NVDA) bucked the trend, rising 0.7% after JPMorgan suggested that recent declines in the stock presented a buying opportunity. But the stock lost momentum in after-hours ...

“Stronger results on inflation have sparked a renewed angst over the trajectory for interest rates, which is feeding more broadly into concerns over the economic outlook,” Westpac analysts said in a ...

Investing.com -- S&P Global Ratings has revised its outlook for CCL Industries Inc. to positive from stable, while affirming the company’s ’BBB’ credit rating. The rating agency cited CCL’s strong ...

According to S&P, the value of the aircraft serving as collateral has proven more resilient than anticipated. The collateral ...

The proposed expansion by Nasdaq follows similar announcements from rivals. The New York Stock Exchange and Cboe Global Markets have also recently announced their own plans to transition toward ...

Investing.com -- Allogene Therapeutics Inc (NASDAQ:ALLO) stock rose 4.9% in after-hours trading on Monday following a favorable arbitration ruling that reaffirmed the company’s control over its cancer ...

Investing.com -- Accuray Incorporated (NASDAQ:ARAY) stock rose 5.7% in after-hours trading Monday following the announcement of a comprehensive transformation plan aimed at improving profitability by ...

"2025 has been a year of significant accomplishments where we advanced key clinical trials and launched an important new treatment for people living with a specific type of LGSOC, a rare ovarian ...